THE ROLE OF GENOMIC SCREENING IN TRANSFORMING PUBLIC HEALTH Understanding ethical, legal & social impacts of genomic screening
With
Dr Jane Tiller, Ethical, Legal & Social Adviser,
Public Health Genomics, Monash University
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | July 2025
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
Jane also focusses on identifying and addressing the ethical, legal and social barriers to public acceptability and uptake of genetic screening. She co-founded the Australian Genetic Non-Discrimination Working Group, and led a project from 2020-2023 about genetic discrimination in life insurance. Jane led significant advocacy efforts towards translating her research findings into real world policy change. She was instrumental in the Government’s 2024 announcement that it will legislate a total ban on the use of genetic results in life insurance underwriting. Jane’s work has been recognised through a number of competitive awards, including recently the prestigious 2024 Research Australia Advocacy Award.
Source: Supplied
-
New treatment options under investigation for pelvic organ prolapse
Dr Shayanti Mukherjee, Research Group Head, Translational Tissue Engineering at the with her team at Hudson Institute of Medical Research is developing new ways to prevent and potential cure pelvic organ prolapse (POP). The technology aims to ultimately lead to safer and more effective treatment for women with pelvic organ prolapse (POP) using a woman’s own stem cells to boost the effectiveness of a degradable mesh.
-
Jamie Stanistreet talks Medical Technology
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific -
Health Minister appoints Chair to National One Stop Shop Program
The Australian Government has appointed Emeritus Professor Ian Chubb AC, FAA FTSE to lead key reforms as Chair of the Inter-Governmental Policy Reform Group (IGPRG) for health and medical research, including clinical trials.
Minister for Health and Aged Care, The Hon Mark Butler MP commenting on the selection and appointment said, “Professor Chubb has dedicated his career to improving health and medical research and education in this county and I am pleased he has agreed to share his knowledge and experience through the IGPRG.”
